Does the media prefer EYPT or MASS?

In the previous week, Eyepoint Pharmaceuticals had 6 more articles in the media than 908 Devices. MarketBeat recorded 8 mentions for Eyepoint Pharmaceuticals and 2 mentions for 908 Devices. Eyepoint Pharmaceuticals' average media sentiment score of 0.32 beat 908 Devices' score of 0.23 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eyepoint Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral 908 Devices 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, TRNS or MASS?

908 Devices has lower revenue, but higher earnings than Transcat. 908 Devices is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Transcat $331.88M 2.42 $5.38M $0.58 148.43 908 Devices $56.20M 4.73 $19.49M -$1.00 N/A

Is TRNS or MASS more profitable?

Transcat has a net margin of 1.62% compared to 908 Devices' net margin of -62.40%. Transcat's return on equity of 5.84% beat 908 Devices' return on equity. Company Net Margins Return on Equity Return on Assets Transcat 1.62% 5.84% 3.78% 908 Devices -62.40% -14.03% -10.40%

Does the media prefer TRNS or MASS?

In the previous week, Transcat had 2 more articles in the media than 908 Devices. MarketBeat recorded 4 mentions for Transcat and 2 mentions for 908 Devices. Transcat's average media sentiment score of 0.90 beat 908 Devices' score of 0.23 indicating that Transcat is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Transcat 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive 908 Devices 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to MASS or CTKB?

In the previous week, 908 Devices and 908 Devices both had 2 articles in the media. Cytek Biosciences' average media sentiment score of 0.96 beat 908 Devices' score of 0.23 indicating that Cytek Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 908 Devices 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Cytek Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MASS or FEIM?

In the previous week, Frequency Electronics had 9 more articles in the media than 908 Devices. MarketBeat recorded 11 mentions for Frequency Electronics and 2 mentions for 908 Devices. 908 Devices' average media sentiment score of 0.23 beat Frequency Electronics' score of 0.00 indicating that 908 Devices is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 908 Devices 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Frequency Electronics 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor MASS or LAB?

In the previous week, Standard BioTools had 2 more articles in the media than 908 Devices. MarketBeat recorded 4 mentions for Standard BioTools and 2 mentions for 908 Devices. Standard BioTools' average media sentiment score of 1.44 beat 908 Devices' score of 0.23 indicating that Standard BioTools is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 908 Devices 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Standard BioTools 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

908 Devices (MASS) Competitors

$7.03 -0.32 (-4.35%)

Closing price 07/20/2026 04:00 PM Eastern

Extended Trading

$7.04 +0.01 (+0.14%)

As of 07/20/2026 07:34 PM Eastern

Compare

MASS vs. EYPT, TRNS, CTKB, FEIM, and LAB

Should you buy 908 Devices stock or one of its competitors? MarketBeat compares 908 Devices with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with 908 Devices include Eyepoint Pharmaceuticals (EYPT), Transcat (TRNS), Cytek Biosciences (CTKB), Frequency Electronics (FEIM), and Standard BioTools (LAB). These companies are all part of the "measuring and control equipment" industry.

How does 908 Devices compare to Eyepoint Pharmaceuticals?

Eyepoint Pharmaceuticals (NASDAQ:EYPT) and 908 Devices (NASDAQ:MASS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership and valuation.

Eyepoint Pharmaceuticals presently has a consensus price target of $43.75, suggesting a potential upside of 245.58%. 908 Devices has a consensus price target of $12.00, suggesting a potential upside of 70.70%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Eyepoint Pharmaceuticals is more favorable than 908 Devices.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eyepoint Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
908 Devices	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Eyepoint Pharmaceuticals had 6 more articles in the media than 908 Devices. MarketBeat recorded 8 mentions for Eyepoint Pharmaceuticals and 2 mentions for 908 Devices. Eyepoint Pharmaceuticals' average media sentiment score of 0.32 beat 908 Devices' score of 0.23 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eyepoint Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
908 Devices	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

908 Devices has higher revenue and earnings than Eyepoint Pharmaceuticals. 908 Devices is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eyepoint Pharmaceuticals	$31.37M	33.84	-$231.96M	-$3.50	N/A
908 Devices	$56.20M	4.73	$19.49M	-$1.00	N/A

908 Devices has a net margin of -62.40% compared to Eyepoint Pharmaceuticals' net margin of -3,566.63%. 908 Devices' return on equity of -14.03% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eyepoint Pharmaceuticals	-3,566.63%	-110.54%	-90.15%
908 Devices	-62.40%	-14.03%	-10.40%

Eyepoint Pharmaceuticals has a beta of 1.73, suggesting that its share price is 73% more volatile than the broader market. Comparatively, 908 Devices has a beta of 0.63, suggesting that its share price is 37% less volatile than the broader market.

99.4% of Eyepoint Pharmaceuticals shares are owned by institutional investors. Comparatively, 88.1% of 908 Devices shares are owned by institutional investors. 5.1% of Eyepoint Pharmaceuticals shares are owned by insiders. Comparatively, 28.2% of 908 Devices shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Eyepoint Pharmaceuticals beats 908 Devices on 10 of the 17 factors compared between the two stocks.

How does 908 Devices compare to Transcat?

Transcat (NASDAQ:TRNS) and 908 Devices (NASDAQ:MASS) are both small-cap measuring and control equipment companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, profitability, valuation and earnings.

Transcat currently has a consensus target price of $105.50, suggesting a potential upside of 22.55%. 908 Devices has a consensus target price of $12.00, suggesting a potential upside of 70.70%. Given 908 Devices' higher possible upside, analysts plainly believe 908 Devices is more favorable than Transcat.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Transcat	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
908 Devices	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Transcat had 2 more articles in the media than 908 Devices. MarketBeat recorded 4 mentions for Transcat and 2 mentions for 908 Devices. Transcat's average media sentiment score of 0.90 beat 908 Devices' score of 0.23 indicating that Transcat is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Transcat	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
908 Devices	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

908 Devices has lower revenue, but higher earnings than Transcat. 908 Devices is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Transcat	$331.88M	2.42	$5.38M	$0.58	148.43
908 Devices	$56.20M	4.73	$19.49M	-$1.00	N/A

Transcat has a net margin of 1.62% compared to 908 Devices' net margin of -62.40%. Transcat's return on equity of 5.84% beat 908 Devices' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Transcat	1.62%	5.84%	3.78%
908 Devices	-62.40%	-14.03%	-10.40%

98.3% of Transcat shares are held by institutional investors. Comparatively, 88.1% of 908 Devices shares are held by institutional investors. 2.8% of Transcat shares are held by company insiders. Comparatively, 28.2% of 908 Devices shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Transcat has a beta of 0.69, meaning that its stock price is 31% less volatile than the broader market. Comparatively, 908 Devices has a beta of 0.63, meaning that its stock price is 37% less volatile than the broader market.

Summary

Transcat beats 908 Devices on 12 of the 16 factors compared between the two stocks.

How does 908 Devices compare to Cytek Biosciences?

908 Devices (NASDAQ:MASS) and Cytek Biosciences (NASDAQ:CTKB) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, valuation, earnings, institutional ownership and dividends.

In the previous week, 908 Devices and 908 Devices both had 2 articles in the media. Cytek Biosciences' average media sentiment score of 0.96 beat 908 Devices' score of 0.23 indicating that Cytek Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
908 Devices	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cytek Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cytek Biosciences has a net margin of -36.25% compared to 908 Devices' net margin of -62.40%. Cytek Biosciences' return on equity of -10.07% beat 908 Devices' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
908 Devices	-62.40%	-14.03%	-10.40%
Cytek Biosciences	-36.25%	-10.07%	-7.56%

88.1% of 908 Devices shares are owned by institutional investors. Comparatively, 69.5% of Cytek Biosciences shares are owned by institutional investors. 28.2% of 908 Devices shares are owned by insiders. Comparatively, 10.4% of Cytek Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

908 Devices has higher earnings, but lower revenue than Cytek Biosciences. Cytek Biosciences is trading at a lower price-to-earnings ratio than 908 Devices, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
908 Devices	$56.20M	4.73	$19.49M	-$1.00	N/A
Cytek Biosciences	$201.49M	2.94	-$66.54M	-$0.57	N/A

908 Devices has a beta of 0.63, suggesting that its share price is 37% less volatile than the broader market. Comparatively, Cytek Biosciences has a beta of 1.17, suggesting that its share price is 17% more volatile than the broader market.

908 Devices currently has a consensus target price of $12.00, indicating a potential upside of 70.70%. Cytek Biosciences has a consensus target price of $5.69, indicating a potential upside of 24.18%. Given 908 Devices' higher possible upside, analysts plainly believe 908 Devices is more favorable than Cytek Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
908 Devices	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Cytek Biosciences beats 908 Devices on 9 of the 15 factors compared between the two stocks.

How does 908 Devices compare to Frequency Electronics?

908 Devices (NASDAQ:MASS) and Frequency Electronics (NASDAQ:FEIM) are both small-cap measuring and control equipment companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk.

Frequency Electronics has a net margin of -1.43% compared to 908 Devices' net margin of -62.40%. Frequency Electronics' return on equity of -1.55% beat 908 Devices' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
908 Devices	-62.40%	-14.03%	-10.40%
Frequency Electronics	-1.43%	-1.55%	-0.97%

88.1% of 908 Devices shares are held by institutional investors. Comparatively, 58.6% of Frequency Electronics shares are held by institutional investors. 28.2% of 908 Devices shares are held by insiders. Comparatively, 28.0% of Frequency Electronics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

908 Devices has a beta of 0.63, suggesting that its share price is 37% less volatile than the broader market. Comparatively, Frequency Electronics has a beta of 0.71, suggesting that its share price is 29% less volatile than the broader market.

In the previous week, Frequency Electronics had 9 more articles in the media than 908 Devices. MarketBeat recorded 11 mentions for Frequency Electronics and 2 mentions for 908 Devices. 908 Devices' average media sentiment score of 0.23 beat Frequency Electronics' score of 0.00 indicating that 908 Devices is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
908 Devices	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Frequency Electronics	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

908 Devices currently has a consensus price target of $12.00, suggesting a potential upside of 70.70%. Frequency Electronics has a consensus price target of $43.67, suggesting a potential downside of 34.55%. Given 908 Devices' higher probable upside, equities research analysts plainly believe 908 Devices is more favorable than Frequency Electronics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
908 Devices	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Frequency Electronics	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.00

908 Devices has higher earnings, but lower revenue than Frequency Electronics. Frequency Electronics is trading at a lower price-to-earnings ratio than 908 Devices, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
908 Devices	$56.20M	4.73	$19.49M	-$1.00	N/A
Frequency Electronics	$63.23M	10.38	-$900K	-$0.09	N/A

Summary

Frequency Electronics beats 908 Devices on 10 of the 16 factors compared between the two stocks.

How does 908 Devices compare to Standard BioTools?

908 Devices (NASDAQ:MASS) and Standard BioTools (NASDAQ:LAB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and dividends.

Standard BioTools has a net margin of 73.46% compared to 908 Devices' net margin of -62.40%. Standard BioTools' return on equity of -8.18% beat 908 Devices' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
908 Devices	-62.40%	-14.03%	-10.40%
Standard BioTools	73.46%	-8.18%	-6.43%

908 Devices has a beta of 0.63, indicating that its stock price is 37% less volatile than the broader market. Comparatively, Standard BioTools has a beta of 1.42, indicating that its stock price is 42% more volatile than the broader market.

908 Devices presently has a consensus target price of $12.00, suggesting a potential upside of 70.70%. Standard BioTools has a consensus target price of $1.35, suggesting a potential upside of 58.82%. Given 908 Devices' stronger consensus rating and higher possible upside, equities analysts clearly believe 908 Devices is more favorable than Standard BioTools.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
908 Devices	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Standard BioTools	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, Standard BioTools had 2 more articles in the media than 908 Devices. MarketBeat recorded 4 mentions for Standard BioTools and 2 mentions for 908 Devices. Standard BioTools' average media sentiment score of 1.44 beat 908 Devices' score of 0.23 indicating that Standard BioTools is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
908 Devices	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Standard BioTools	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

88.1% of 908 Devices shares are held by institutional investors. Comparatively, 53.7% of Standard BioTools shares are held by institutional investors. 28.2% of 908 Devices shares are held by insiders. Comparatively, 26.8% of Standard BioTools shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

908 Devices has higher earnings, but lower revenue than Standard BioTools. 908 Devices is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
908 Devices	$56.20M	4.73	$19.49M	-$1.00	N/A
Standard BioTools	$85.33M	3.89	-$74.90M	$0.20	4.25

Summary

Standard BioTools beats 908 Devices on 9 of the 16 factors compared between the two stocks.

Get 908 Devices News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MASS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MASS vs. The Competition

Export

Metric	908 Devices	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$277.93M	$7.42B	$6.89B	$12.28B
Dividend Yield	N/A	1.32%	2.67%	9.39%
P/E Ratio	-7.03	49.51	27.07	23.95
Price / Sales	4.73	49.42	515.72	90.33
Price / Cash	N/A	26.91	26.68	47.25
Price / Book	1.77	6.96	10.62	6.14
Net Income	$19.49M	$162.27M	$3.60B	$331.74M
7 Day Performance	-13.85%	-0.45%	-1.26%	-1.82%
1 Month Performance	-20.48%	-1.58%	1.07%	-1.45%
1 Year Performance	1.01%	6.48%	23.63%	16.32%

908 Devices Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MASS 908 Devices	2.273 of 5 stars	$7.03 -4.4%	$12.00 +70.7%	+4.9%	$277.93M	$56.20M	N/A	60	Analyst Downgrade
EYPT Eyepoint Pharmaceuticals	3.1643 of 5 stars	$14.16 -0.9%	$44.29 +212.8%	+21.5%	$1.19B	$31.37M	N/A	120
TRNS Transcat	3.5816 of 5 stars	$90.21 -2.3%	$105.50 +17.0%	+5.9%	$842.52M	$331.88M	155.53	1,413
CTKB Cytek Biosciences	3.4914 of 5 stars	$4.64 +2.8%	$5.69 +22.7%	+46.3%	$598.56M	$201.49M	N/A	500
FEIM Frequency Electronics	1.374 of 5 stars	$57.98 +6.4%	$43.67 -24.7%	+210.8%	$570.52M	$69.81M	77.31	200	Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MASS) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

908 Devices (MASS) Competitors

MASS vs. EYPT, TRNS, CTKB, FEIM, and LAB

How does 908 Devices compare to Eyepoint Pharmaceuticals?

Summary

How does 908 Devices compare to Transcat?

Summary

How does 908 Devices compare to Cytek Biosciences?

Summary

How does 908 Devices compare to Frequency Electronics?

Summary

How does 908 Devices compare to Standard BioTools?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MASS vs. The Competition

908 Devices Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

908 Devices (MASS) Competitors

MASS vs. EYPT, TRNS, CTKB, FEIM, and LAB

How does 908 Devices compare to Eyepoint Pharmaceuticals?

Do analysts rate EYPT or MASS?

Does the media prefer EYPT or MASS?

Which has preferable earnings & valuation, EYPT or MASS?

Is EYPT or MASS more profitable?

Which has more volatility and risk, EYPT or MASS?

Do insiders & institutionals hold more shares of EYPT or MASS?

Summary

How does 908 Devices compare to Transcat?

Do analysts prefer TRNS or MASS?

Does the media prefer TRNS or MASS?

Which has preferable earnings and valuation, TRNS or MASS?

Is TRNS or MASS more profitable?

Do insiders and institutionals hold more shares of TRNS or MASS?

Which has more volatility and risk, TRNS or MASS?

Summary

How does 908 Devices compare to Cytek Biosciences?

Does the media refer more to MASS or CTKB?

Is MASS or CTKB more profitable?

Do insiders & institutionals have more ownership in MASS or CTKB?

Which has preferable valuation and earnings, MASS or CTKB?

Which has more volatility & risk, MASS or CTKB?

Do analysts prefer MASS or CTKB?

Summary

How does 908 Devices compare to Frequency Electronics?

Is MASS or FEIM more profitable?

Do institutionals & insiders hold more shares of MASS or FEIM?

Which has more risk & volatility, MASS or FEIM?

Does the media favor MASS or FEIM?

Do analysts prefer MASS or FEIM?

Which has preferable valuation & earnings, MASS or FEIM?

Summary

How does 908 Devices compare to Standard BioTools?

Is MASS or LAB more profitable?

Which has more volatility & risk, MASS or LAB?

Do analysts recommend MASS or LAB?

Does the media favor MASS or LAB?

Do institutionals & insiders hold more shares of MASS or LAB?

Which has stronger valuation & earnings, MASS or LAB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MASS vs. The Competition

908 Devices Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools